| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |